Mindfulness based interventions (MBI) may be an effective treatment for sexual dysfunction among men and women. A literature review identified seven trials for sexual dysfunction and MBI. Of these, four trials were Randomised Control Trials (RCTs) including a control-group wait list and three studies used within-subjects design. A meta-analysis synthesized the results across these trials which demonstrated an overall low to moderate effect size (Cohen’s d = 0.55). Moderate heterogeneity between studies was evident with possible publication bias. Sub-group analysis revealed differences between study weights, where overall higher effect sizes were found among RCTs (d = 0.65) than within subject design studies (d = 0.27). However, within subject design studies tended to include pre and post-physiological measurements (e.g. vaginal photoplethysmography), which may provide a more precise evaluation of the benefits of MBI, rather than studies based on self-report measures only. This review identified a gender inequality in which clinical trials predominated among women compared to men with a 6:1 ratio. Whilst MBI looks promising, significantly more research is needed, particularly among men, so that science, practice and policy can develop an understanding of the potential benefits of non-prescription intervention alternatives, or as a biopsychosocial adjunct, such as MBI, in support of those experiencing sexual dysfunction.
Sexual intimacy is a basic human need that is associated with quality of life whereby its absence can significantly impact both interpersonal and personal wellbeing. This systematic review aimed to provide an up-to-date evaluation of the available literature on mindfulness treatments for sexual functioning in women diagnosed with cancer. Electronic searches including PubMed, PsycINFO, Web of Science and registered clinical trials yielded 10 studies that met the inclusion criteria. The results showed that treatment intervention designs varied and included mixed methods, randomised clinical trials, single arm non-randomised trials and those with the absence of any control. Furthermore, both brief and longer-term mindfulness interventions were trialled across different sexual domains. Whilst inconclusive, mindfulness-based interventions appear to support sexual function and quality of life in both early- and post-cancer survivors. However, in some instances, there were outcome inconsistencies in sexual desire, arousal and orgasm. This review has identified a current shortage in research on the effectiveness of mindfulness-based treatments for supporting sexual functioning in women with cancer; and so far, no research has been conducted in palliative care. This unmet need in supporting sexual functioning in women with cancer, including palliative care, carries important implications for both psychosexual and oncological healthcare services as sexual intimacy does not end with cancer diagnosis or prognosis.
5 September 2018 in MOJ Addiction Medicine & Therapy
This systematic review aims to provide an up-to-date evaluation of the available literature on anodyspareunia and treatment interventions. It aims to identify research gaps and to evaluate treatment methods in psychosexual healthcare services. Electronic searches including PubMed, PsycINFO, Web of Science, and registered clinical trials yielded 8 studies. Research centered on men who have sex with men (MSM) and cisgender women with a 3:1 ratio. In terms of causes of anodyspareunia, correlates among both MSM and cisgender women included generalized anxiety, performance anxiety, compromised well-being, lack of stimulation, lack of lubrication, and lack of sexual arousal. While research has focused on anodyspareunia among cisgender gay men, limited research has targeted other genders or sexualities including heterosexual men and lesbian and bisexual women. No research was found on intersex, transgender, and gender nonconforming people. Similarly, there were no articles that discussed or evaluated treatment strategies. The findings of this review demonstrate the paucity of research on both the condition of anodyspareunia and its treatment across genders and sexually diverse groups. Both quantitative and qualitative research would not only develop our understanding of anodyspareunia but also contribute to public health through the development of suitable treatment interventions.
28 February 2022 in Sexual and Relationship Therapy
Background: Research has predominated among the therapeutic application of psychedelics for varied psychopathologies and yet remains limited when supporting sexual behaviour intimacy among couples; particularly those who micro-dose. Method: Using semi-structured interviews, this qualitative study explored the micro-dosing sexual experiences of four partnered men and women aged 20–35 years. Interviews examined the effect of micro-dosing on confidence, openness, sexuality, inhibition and perceived relationship satisfaction. Results: Thematic analysis identified three key narratives: increased sexual self-efficacy; sexual exploration; and heightened relationship satisfaction. From the participant’s perspective, the use of micro-dosing psychedelics had a positive effect on sexual and physical well-being by reducing stress and performance-related anxiety. This, in turn, elevated sexual desire, exploration, communication and enhanced sensory and sexual experience, thus potentially supporting emotional and physical connection. In terms of erectile functioning and orgasm, participants attributed this to being micro-dose and psychedelic choice dependent. Whilst higher doses of MDMA hindered sexual functioning this did not negatively impact the emotional and sensory experiences. Conclusion: These findings point to micro-dosing psychedelics as offering a potentially beneficial adjunct to psychosexual and couple’s therapy; potentiating relationship and sexual satisfaction. Further research might wish to gravitate quantitatively towards a larger and varied micro-dosing populace in supporting sexual self-efficacy and intimacy.
Background and Objectives: The impact of gynaecological cancer and its treatments on sexual intimacy can be profound on female sexuality. However, very few registered clinical trials have addressed sexual intimacy among this cohort. Materials and Methods: This preliminary randomised control trial (RCT) and content analysis assessed the effectiveness of a brief online mindful compassion group intervention adjunct with cannabis suppositories. Eighty-three participants aged between 18 and 50+ years who were at least six months post-cancer treatment were randomly allocated to one of four groups, depending on whether they were already using cannabis suppositories. These included a cannabis-only group (CO), a mindful-compassion group (MC), a combined mindful-compassion and cannabis suppositories group (COCM) and a care-as-usual group (CAU). Measurements of sexual function, sexual self-efficacy, mindful compassion, well-being and quality of life were taken at weeks 0, 4 and 12. Results: Sexual function, including arousal, lubrication and orgasms, improved for both the MC p = 0.002 and COCM p ≤ 0.001 groups; in addition, sexual pain was reduced in the COCM p = 0.008 and CO p ≤ 0.001 groups compared to the CAU and MC groups, where p ≥ 0.05. Feedback suggested that cannabis mediated the effects of mindful compassion and supported well-being, sexual self-efficacy, and quality of life. Participants also voiced a preference for cannabis suppositories when using dilators as part of their treatment and the use of sex toys instead of dilators, suggesting that dilators had negatively impacted their sexuality. Conclusions: These preliminary and exploratory outcomes look promising and provide a foundation for future research to develop varied healthcare options to improve mental health service delivery and quality of life for this cohort.